
å»çAIã®æ¬åœã®é害ã¯ãæè¡ãããªããŠå©æš©ãšå¶åºŠã®æ¹ãããããªã
å»ç AI ãšèããšãæåã¯ãç»å蚺æãšããå蚺ã®èªååãšãã§ããããšããã€ã¡ãŒãžã§æ¢ãŸããã¡ã§ãã
å®éãAI ã CT ç»åããèºãããèŠã€ãããAI ãçŒåºåçããç³å°¿ç æ§ç¶²èçãæ€åºãããAI å蚺ã§å蚺åã«çç¶ãæŽçãããããããæè¡ã¯ãããã«ãããã
ãã ãå»çå¶åºŠã®è°è«ã远ããããŠãããšããã£ãšæåã«ããåé¡ãèŠããŠããŸãã
å»çã®äžçã«ã¯ãAI 以åãããã§ã«ãåççã«å€ããæ¹ããããããªã®ã«ããªããå€ãããªããã®ãããããŸãã
äŸãã°ãèºã¬ã³ãã²ã³ãããªãŠã æ€æ»ãABCæ€æ»ãHPVæ€æ»ã
ãããã¯ãAI ã«ãã£ãŠåããŠå¯èœã«ãªã£ããã®ã§ã¯ãããŸãããããã AI 以åããããæ¬åœã«ä»ã®ãŸãŸã§ããã®ãããšèšãããŠããé åã§ãã
æ€æ»é åã«éãããå»ç AI ãå¶åºŠãæ¢åæ§é ã«é»ãŸããå Žé¢ã¯ãã»ãã«ãããã€ããããŸãããã ãããã§ã¯åãããããäŸãšããŠãããããåãäžããŸãã
ããªãŠã æ€æ»ã¯ãçŸä»£ã®æ€èšºãšããŠä»ãªãäžå¿ã«çœ®ãç¶ããåçæ§ãããªã匱ããªã£ãŠããããã«èŠããŸãã
HPV æ€æ»ã HPV èªå·±æ¡åã¯ãåå®®é žããæ€èšºã®å蚺çãå蚺è
ã®è² æ
ãèããã°ããã£ãšåºãã£ãŠããã¯ãã§ãã
ABCæ€æ»ããããªè察çã¯ãèããããèŠã€ãããããåã«ããªã¹ã¯ãå±€å¥åããäºé²ã«å¯ããçºæ³ã§ãã
èºã¬ã³ãã²ã³ããèºããæ€èšºã®ããæ¹ãšããŠãæ¬åœã«ä»ã®åœ¢ãæé©ãªã®ããšããè«ç¹ããããŸãã
ããã§ããå€ãããªãã
çç±ã¯ãæè¡ã§ã¯ãããŸãããå¶åºŠãšå©æš©ã§ãã
æ€æ»æ©åšãå¥èšºæ©é¢ã®ãªãã¬ãŒã·ã§ã³ãå°éè·å£äœãåŠäŒãå»åž«äŒã蚺çå ±é ¬ã察çåæ€èšºã®æéãã¬ã€ãã©ã€ã³ããããããã®ã絡ããšãåççã«èŠãã倿Žã§ãç°¡åã«ã¯é²ã¿ãŸããã
ããããå»ç AI ãèããããã§ãéèŠã§ãã
AI ã§èšºæç²ŸåºŠãäžãããAI ã§äºé²ä»å ¥ããããããªããAI ã§å»çè³æºãå¹çåã§ããã
ããããæè¡è«ã ãã§ã¯ãå»çã¯åããŸããã
å»ç AI ã®æ¬åœã®é害ã¯ãæè¡ãã®ãã®ã§ã¯ãªããæè¡ã瀟äŒå®è£ ããããã«éããªããã°ãªããªãå¶åºŠãšå©æš©ã®æ¹ã«ããã®ã§ã¯ãªããã
ãã®èšäºã§èŠããã®ã¯ãããã§ãã
AI 以åããããåççã§ãå€ãããªãå»çãããã

å»ç AI ã®è©±ãå§ããåã«ããŸã確èªããŠããããããšããããŸãã
æ¥æ¬ã®å»çã«ã¯ãAI ãç»å Žããåãããæè¡çã«ã¯ããåççãªä»£æ¿ãããã®ã«ãçŸå Žã§æ®ãç¶ããŠããæ€æ»ãè€æ°ãããŸãã
åé ã§æãã 4 ã€ã¯ããã®ä»£è¡šäŸã§ãã
èºã¬ã³ãã²ã³: ããšã¯æŠåŸã®çµæ žæ€èšºãšããŠå§ãŸã£ãæ€æ»ãçŸä»£ã®äž»ç®çã§ããèºããæ€èšºãšããŠã¯ãäœç·é CT ã®æ¹ãæåºŠãé«ãããšãå€§èŠæš¡èšåºç ç©¶ã§ç€ºãããŠãã
ããªãŠã æ€æ»: èããæ€èšºã®äž»è»žãšããŠæ®ã£ãŠãããã被ã°ãã»èª€å¥ã»è žéå¡ãªã©ã®ãªã¹ã¯ããããå èŠé¡ããªã¹ã¯å±€å¥ååã®æ€æ»ãšãã代æ¿ããã
HPV æ€æ»ã»HPV èªå·±æ¡å: åå®®é žããæ€èšºã§ WHO ãäžæ¬¡æ€æ»ãšããŠæšå¥šããŠããããæ¥æ¬ã§ã¯çްè蚺äžå¿ã®äœå¶ãæž©åãããèªæ²»äœå®è£ ã¯é ããŠãã
ABC æ€æ»: æ¡è¡ã®ã¿ã§èãããªã¹ã¯ãå±€å¥åã§ããæ€æ»ããèŠã€ãããããåã«ããªã¹ã¯ãåãããäºé²åã®çºæ³
ãããã«å ±éããŠããã®ã¯ãæè¡çã«ã¯ããåççãªä»£æ¿ãããã®ã«ãæ¥æ¬ã®çŸå Žã§ã¯äŸç¶ãšããŠå€ãæ€æ»ãäž»è»žã«æ®ã£ãŠããããšããäºå®ã§ãã
ãããŠãå€ãããªãçç±ã¯ãæè¡ã®é ãã§ã¯ãããŸããã
å¥èšºæ©é¢ã®æ€æ»ã©ã€ã³ãèªåœ±äœå¶ãæ¢åèšåãå°éè·å£äœã®ç«å Žãæ€æ»æ©åšã¡ãŒã«ãŒãšã®é¢ä¿ã蚺çå ±é ¬ã®ç¹æ°èšèšã察çåæ€èšºã®æéãã¬ã€ãã©ã€ã³ã®ä¿å®æ§ããããããã®ãè€éã«çµ¡ãã§ããã
ã€ãŸããå»çã«ã¯ãåççã«å€ããæ¹ãããããããšãå¶åºŠãšããŠå€ãã«ãããã®ããã ã«ãæ³å以äžã«æ·±ãæºããããŸãã
å»ç AI ãåºãŠããŠãããã®æºãã®ãã®ãæ¶ããããã§ã¯ãããŸããã
ããããAI ãããã£ãšå¹ççã«ã§ããã¯ãããäºé²ã®æ¹ãå®ãæžãã¯ãããšããã¢ã€ãã¢ãçããã³ã«ãåãå£ã«ã¶ã€ããã
ããããå ã¯ããã®æ§é ã 3 ã€ã®å ·äœäŸã§èŠãŠãããŸãã
å»ç AI ãåºããç¯å²ã¯ãæ³åããåºã

å ·äœäŸã«å ¥ãåã«ãããå°ãã ãåæãå ±æããŠãããŸããå»ç AI ã®å°çšã¯ãç»å蚺æãå蚺ã®èªååã«çãŸããŸãããæè¡é¢ãšäºé²ã»ç¶ç¶æ¯æŽé¢ã®äž¡è»žã§ãããªãåºãç¯å²ãã«ããŒããŸãã
æè¡é¢ã®ä»£è¡šäŸ:
AI ç»å蚺æ: èžéš CT ããèºããã®å åãèŠã€ãããçŒåºåçããç³å°¿ç æ§ç¶²èçãæ€åºããããã¯ãã®åçããç®èããçããå€å®ããããã³ã¢ã°ã©ãã£ããä¹³ããåè£ãæœåºãã
AI ç ç蚺æ: çµç¹ãµã³ãã«ã®é¡åŸ®é¡ç»åããããã现èã®æç¡ã AI ãäžæ¬¡å€å®ãã
AI åµè¬: éå»ã®ååç©ããŒã¿ãããæ°è¬ã®åè£ãçµã蟌ããéçºæéãå€§å¹ ççž®ããå¯èœæ§
æè¡ããããæ¯æŽ: å€ç§å»ã®æã®éãã AI ãè£æ£ããã粟å¯ãªæè¡ãå®çŸãã
AI ã²ãã è§£æ: éºäŒåããŒã¿ããçŸæ£ãªã¹ã¯ãè¬å€åå¿æ§ãäºæž¬ãã
äºé²ã»ç¶ç¶æ¯æŽé¢ã®ä»£è¡šäŸ:
AI å蚺: å蚺åã«ã¹ããã§çç¶ãæŽçãå»åž«ã®è³ªåæéãççž®
çæŽ»ç¿æ £æ¹åæ¯æŽ: ãŠã§ã¢ã©ãã«ã®ããŒã¿ããåå¥ã®æ¹åææ¡
æè¬ç®¡ç: 飲ã¿å¿ã鲿¢ãå¯äœçšã®æ©ææ€ç¥
é«éœ¢è èŠå®ã: åšå® ã¢ãã¿ãªã³ã°ã§ç°åžžã®æ©æçºèŠ
æ ¢æ§çŸæ£ç®¡ç: ç³å°¿ç ã»é«è¡å§ã®ç¶ç¶æ¯æŽãæªååã®ä»å ¥
ã¡ã³ã¿ã«æ¯æŽ: äŒè©±ããŒã¹ã®æ©æä»å ¥ãå°éå»ãžã®æ¥ç¶
æè¡ãšããŠãã§ããã / ã§ããªãããã®è°è«ã§èšãã°ãäžèšã®å€ã㯠2026 幎çŸåšãããã§ããŠããŸãã
åé¡ã¯ãããããæ¥æ¬ã®å»ççŸå Žã§ã©ããŸã§å®è£ ãããä¿éºèšºçã«çµã¿èŸŒãŸããŠããããã§ãã
æ¥æ¬å»çã®åŒ·ã¿ãšãæ§é çãªæªã¿
å ·äœäŸãèŠãåã«ãããã²ãšã€åæãæŽçããŠãããŸããæ¥æ¬å»çã«ã¯åŒ·ã¿ãããããæ§é çãªæªã¿ããããäž¡æ¹ãèžãŸããªããšè°è«ãçå¯ããŸãã
匷ã¿ã®æ¹ã¯ãã¯ã£ããããŠããŸãã
åœæ°çä¿éº: å šåœæ°ãå»çä¿éºã«å å ¥ãç¡ä¿éºè ã®å»çã¢ã¯ã»ã¹åé¡ãå°ãã
ããªãŒã¢ã¯ã»ã¹: æ£è ãå»çæ©é¢ãèªç±ã«éžã¹ãïŒç޹ä»ç¶ãªãã§ãããããïŒ
å»çæ°Žæºã®é«ã: å¹³å寿åœã5 幎çåçãä¹³å¹Œå æ»äº¡çãªã©ã®ææšã§äžçãããã¯ã©ã¹
èªç±éæ¥å¶: å»åž«ãæ¯èŒçèªç±ã«èšºçæãéãã
æ¯èŒçäœãèªå·±è² æ : 3 å²è² æ ïŒé«éœ¢è ã¯ããã«äœãïŒ
å»çã¢ã¯ã»ã¹ã®å ¬å¹³æ§ã¯æµ·å€ãšæ¯ã¹ãŠãçªåºããŠããŸãã
äžæ¹ã§ãæ§é çãªæªã¿ãæç¢ºã§ãã
å»åž«ååš: éœåžéšã«å»çæ©é¢ãéãŸããããããžãå°ãé¢å³¶ã§ã¯å»åž«äžè¶³ãèµ·ããããã蚺çç§ã§èŠããšãå ç§ã¯çŽ 6 äžäººããäžæ¹ã§ãå°å ç§ã¯çŽ 1 äž 8 å人ãç£å©Šäººç§ã»ç£ç§ã¯çŽ 1 äž 2 åäººèŠæš¡ã§ãïŒååŽçã什å 4 幎å»åž«ã»æ¯ç§å»åž«ã»è¬å€åž«çµ±èšãïŒãè² è·ããªã¹ã¯ãé«ãé åã¯ãæ ãæäžè¶³ã«ãªããããæ§é ã§ããååŽçã¯ãå»åž«ååšå¯Ÿçç·åç察çããã±ãŒãžãã 2024 幎 12 æã«å ¬è¡šããŠããŸãããå°åååšè§£æ¶ã®ç®æšã¯ 2036 幎床 ãšã10 幎以äžãããé·ææŠã§ãã
倿¥èšºçã«ãããåºæ¥é«æãäžå¿ã®æ§é : å ¥é¢å»çã§ã¯ DPCïŒèšºæçŸ€åé¡å æ¬è©äŸ¡ïŒãšããå æ¬æããäžéšå°å ¥ãããŠããŸãããããã¯ å ¥é¢ã®ã¿ã察象ã§ã倿¥ã¯åºæ¥é«æããäžå¿ã§ãã蚺çè¡çºãçºçããŠåããŠå ±é ¬ãã€ãä»çµã¿ã§ããç æ°ãé²ãããéçåãé²ãããå蚺åã«çæŽ»ãæŽããããšãã£ã掻åã¯ãæ¬æ¥äŸ¡å€ãããã¯ããªã®ã«ãçŸè¡å¶åºŠã§ã¯è©äŸ¡ããã«ããã
ãããŸã§ããå ¬éè³æããŒã¹ã§æŽçã§ããåæã§ãã
ããããå ãå»çã®çŸå Žã§äœãèµ·ããŠããããã3 ã€ã®å ·äœäŸã§èŠãŠãããŸãã
AI ã§è§£ããŠã婿š©ã§æœ°ããã â 3 ã€ã®å ·äœäŸ

å»ççŸå Žã§åã人ããå»çæ¥çã«è©³ãã人ãšè©±ããŠãããšãæè¡çã«ã¯ãšãã«è§£æ±ºã§ãã課é¡ããæ¥æ¬ã§ã¯åããªããŸãŸã«ãªã£ãŠããçŸè±¡ãããã€ãããããšãã話ãèããŸãã
ãããã®èæ¯ã«ããã®ã¯ãæè¡ã®é ãã§ã¯ãªããæ¢åã®æ€æ»ã蚺çã®æ çµã¿ãç¶æãããæ¢åã¹ããŒã¯ãã«ããŒã®å©å®³ããããŠãã¬ã€ãã©ã€ã³ãäœãåŽãã®ä¿å®çãªã€ã³ã»ã³ãã£ãã§ãã
3 ã€ã®å ·äœäŸããåã圢åŒïŒâ äœã®ããã®æ€æ»ã â â¡åŒ±ç¹ â â¢æ°å â â£ä»£æ¿æ¡ â â€åããªãçç±ïŒã§èŠãŠãããŸãã
â èºã¬ã³ãã²ã³ â æ©æçºèŠã®ããã®æ€æ»ãªã®ã«ãæ©æèºããã«åŒ±ã
â äœã®ããã®æ€æ»ã: å¥åº·èšºæã§å¿ ãåããèžéš X ç·ïŒèºã¬ã³ãã²ã³ïŒãå ã ã¯æŠåŸã®çµæ žæ€èšºãšããŠå§ãŸã£ãæ€æ»ã§ãããçŸä»£ã®äž»ãªç®ç㯠èºããã®æ©æçºèŠã«ç§»ã£ãŠããŸãã
â¡æ€æ»ã®åŒ±ç¹: ãšãããããã®ãæ©æçºèŠããšããç®çã«å¯ŸããŠãèžéš X ç·ã¯ããããæ§é çã«åŒ±ãæ€æ»ã§ããåŒåžåšå ç§ãå¥èšºæ©é¢ã®æšæºè§£èª¬ã§ã¯ãèžéš X ç·ã§æç¢ºã«ç å€ãšããŠèªèã§ããã®ã¯ 2cm 以äžã®ãµã€ãºã§ã1cm 以äžã®è «çã¯ã»ãšãã©æ ããªãããšèª¬æãããããšãå€ãé åã§ããå¿èã»èéªšã»æšªéèãšéãªãäœçœ®ã«ããããã¯æ»è§ã«ãªãããããæ©æèºããã«å€ããããã¬ã©ã¹çµç¯ããšåŒã°ããã¿ã€ãïŒèãåºããåææ®µéã®ããã®æ ãæ¹ïŒã¯ãæ£åžžãªèºã®æš¡æ§ã«çŽããŠæ·¡ãããæ ããªãããšããææããããŸãã
â¢æ°å: åçåŽåçã®æ€èšäŒè³æã§ã¯ã2cm æªæºã®èºããã§ã¯èžéš X ç·ã¯ 79% ãæ€åºã§ãããCT ã¯çŽ 5 åã®æåºŠãããããšããã㊠äœç·é CT ã§ã¯ç æâ ã®èºããïŒæ©ææ®µéã®ããïŒã 60ã80% ã§èŠã€ããäžæ¹ãåŸæ¥ã®èžéš X ç·ã§ã¯ 30ã40% ã«ãšã©ãŸãããšãæŽçãããŠããŸãïŒååŽçãèžéšã¬ã³ãã²ã³ãå«ãæ€èšºã®ã¡ãªããããã¡ãªããã«ã€ããŠãæ€èšäŒè³æïŒãç±³åœã®å€§èŠæš¡èšåºè©Šéš NLSTïŒNational Lung Screening TrialïŒã§ããäœç·é CT ã«ããèºããæ»äº¡çã¯èžéš X ç·ãã çŽ 20% äœãã£ãããšããçµæãå ±åãããŠããŸãã
ã€ãŸããæ©æçºèŠãç®çãªã®ã«ãèå¿ã®æ©ææ®µéã®ãããé«é »åºŠã§åãããŒããããã¯æè¡ä»¥åã«ãæ€æ»èšèšãšããŠããªãå³ãã話ã§ãã
â£çŸä»£çãªä»£æ¿æ¡: äœç·é CT ãå°ããªç å€ãŸã§æŸããAI ç»å蚺æãšçµã¿åãããã°èªåœ±å¹çãããã«äžãããŸããå®éã2025 幎 10 æã®ååŽçãããæ€èšºã®ããæ¹ã«é¢ããæ€èšäŒãã§ã2026 幎床ããå«ç ææ° 600 以äžã®éå«ç è ã察象ã«äœç·é CT æ€èšºã察çåãšããŠå°å ¥ããé·å¹Žå®æœãããŠããåç°çްè蚺ã廿¢ããããšã決ãŸããŸãããåããªãæ§é ã®äžã§ãããšããã³ã¹ã®èç©ãšæ€èšºã€ã³ãã©ã®æŽåãæã£ãé åã§ã¯ãããããäžéšãåãå§ããŠããŸãã
â€ããã§ãå€ãããªãçç±: ããã§ããé壿€èšºã®äž»è»žã¯äŸç¶ãšããŠèžéš X ç·ã®ãŸãŸã§ããããã«ã¯æè¡ã®åé¡ã§ã¯ãªããæ¢åã®æ€èšºæ©é¢ã®æ©ææè³ãæ€æ»ãªãã¬ãŒã·ã§ã³ãå¥èšºã¡ãã¥ãŒã®ä»çµã¿ãä¿éºç¹æ°ã®èšèšãšãã£ãã瀟äŒå®è£ åŽã®æ £æ§ããããŸãããããéå»ã®æ€æ»ã«æ»ããªãæ§é ãããæ€èšºçŸå Žã»å¥èšºç£æ¥ã»èšºçå ±é ¬ã®äžå±€ã§åºå®ãããŠããããšããããšã§ãã
â¡ããªãŠã æ€æ» ãš ABCæ€æ» â æ©æçãã»ãŒçºèŠã§ããªãããªãŠã ãšããªã¹ã¯ã§åãã ABC ã®å¯Ÿæ¯
â äœã®ããã®æ€æ»ã: èããã®æ©æçºèŠãç®çã§ãå¥èšºã®äž»è»žãšããŠé·å¹Ž ããªãŠã X ç·æ€æ»ã䜿ãããŠããŸããæ¥æ¬ã®ã¬ã€ãã©ã€ã³ã§ããè X ç·æ€æ»ãšèå èŠé¡æ€æ»ã®äž¡æ¹ã察çåæ€èšºãšããŠæšå¥šãããŠããŸãã
â¡ããªãŠã ã®åŒ±ç¹ïŒæ©æçãã»ãŒçºèŠã§ããªãïŒ: ããªãŠã ã¯ãæ©æèçãæ§é çã«æŸããªãæ€æ»ã§ãã
æ©æèçã¯ããå°ããªã³ããããèã®å£ã«ãžã°ãã€ããããªå¹³åŠãªç å€ããåšå²ã®ç²èãšè²ããããã«éãã ãã®ç å€ããšããŠçŸããããšãå€ãããšãããããªãŠã ã¯ãæ¥æ¬æ¶ååšå èŠé¡åŠäŒã®èª¬æéããçœé»ã®åœ±çµµãèŠãŠããã«ãããããèã®åœ¢ãå¹åžã鿥çã«èгå¯ããã ãã§ãå¹³åŠãªç å€ãè²ã®éãã¯èªèã§ããŸãããäžæ¹ã®å èŠé¡ã¯ãèã®äžãçŽæ¥èгå¯ãããŠãè²ã®å€åãããããªç²èã®éèµ·ãå¹ã¿ãæš¡æ§ã®ã¡ãããèªèã§ããããããæ©æèããã®çºèŠã§ã¯ãæç¶åªããŠããããšååŠäŒã¯æèšããŠããŸãã
ãã®çµæãå»ççŸå Žã§ã¯ãçŸè¡ã®ããªãŠã äžå¿ã®æ€æ»äœå¶ã§ã¯æ©æããã®çºèŠã¯å°é£ããããªãŠã ã§èŠã€ãã£ãŠããã§ã«é²è¡çã«ãªã£ãŠããããšãå€ãããšããææãçãããããŸããã
å蚺è è² æ ã倧ããã被ã°ãã誀å¥ãè žéå¡ã®ãªã¹ã¯ããããæ€æ»åŸãã€ãããæ¥æ¬æ¶ååšããæ€èšºåŠäŒèªã«æ²èŒãããçŽ 101 äžä»¶ã® 5 幎調æ»ã§ã¯ãããªãŠã èª€å¥ 100 äŸãè žéå¡ 4 äŸãè žç®¡ç©¿å 3 äŸãå ±åãããŠããŸãã
â¢æ°åïŒæ©æçã®åãããŒããšæ»äº¡çæžå°å¹æïŒ: æ°åã§ãããã®å³ããã¯ã¯ã£ããåºãŠããŸãã
æ¥æ¬æ¶ååšããæ€èšºåŠäŒã® 2019 幎æ€èšºããŒã¿éèšã«ããã°ãèã«ã¡ã©ã¯ããªãŠã æ€æ»ã®çŽ 2.5 åã®çºèŠçã§ãããã®å·®ã¯ãã®ãŸãŸãæ©æçãã©ããŸã§æŸããããã®å·®ãšããŠè¡šããŠããŸãã
æ»äº¡çæžå°å¹æã®å·®ã¯ããã£ãšé²éªšã«åºãŠããŸãã
éåœã®åœå®¶ããæ€èšºããã°ã©ã ïŒ1,650 äžäººèŠæš¡ãçäŸ 54,418 人ïŒã®ãã¹ãããã»ã±ãŒã¹ã³ã³ãããŒã«ç ç©¶ã§ã¯ãæ€æ»å¥ã®èããæ»äº¡ãªããºæ¯ã次ã®ããã«å ±åãããŠããŸãïŒJun JK et al. Gastroenterology 2017;152(6):1319-1328, PMID: 28147224ïŒã
è X ç·æ€æ»ïŒããªãŠã ïŒ: ãªããºæ¯ 0.98ïŒ95% CI 0.95-1.01ïŒ= çµ±èšåŠçã«ææãªæ»äº¡çæžå°ãªã
èå èŠé¡æ€æ»ïŒèã«ã¡ã©ïŒ: ãªããºæ¯ 0.53ïŒ95% CI 0.51-0.56ïŒ= æ»äº¡ççŽ 47% æžå°
ã€ãŸãã1,650 äžäººèŠæš¡ã§èŠããšãããªãŠã æ€æ»ã¯èããæ»äº¡çãææã«æžãã广ããããã確èªãããŠããªãã®ã«å¯Ÿããå èŠé¡æ€æ»ã¯ååè¿ãæžãããŠãããæ€èšºã®æçµç®çããèããã§äº¡ããªãäººãæžãããããšã ãšããã°ãäž¡è ã®å·®ã¯ãããçšåºŠã®å·®ãã§ã¯ãªããã»ãŒå¥ç©ããšèšã£ãŠããã¬ãã«ã§ãã
æ©æçãæŸããçã§ããåœãæãåã§ããããªãŠã ã¯å èŠé¡ã«å€§ããå£ãããšããããšã§ãã
â£çŸä»£çãªä»£æ¿æ¡ïŒHPV ãšäžŠè¡æ§é ã®äºæ®µèšèšïŒ: ããã§ãåå®®é žããã®è©±ãšã®äžŠè¡æ§é ãæèãããšãèããã®æ€æ»èšèšã¯ããªãæå¿«ã«æŽçã§ããŸãã
åå®®é žããã¯ã»ãŒ 100% ã HPV ææãèæ¯ã«çºçããŸããã ãããHPV æ€æ»ã§ãµããåããŠãéœæ§è ã ã现è蚺ãç²Ÿå¯æ€æ»ã«é²ãããšããäºæ®µèšèšãåççã«ãªãã
èããããŸã£ããåãæ§é ã§ããæ¥æ¬ã§ã¯èããã®çŽ 99% ããããªèææã«èµ·å ããããšããã®ãè€æ°ã®åœå å»çæ©é¢ã»è§£èª¬ã§åºãæµéãã説æã§ããæ¥æ¬ããªã³ãã¯ã¿ãŒåŠäŒã® 2024 幎çã¬ã€ãã©ã€ã³è§£èª¬ã§ãããããªé€èã«ããèããçºçæå¶å¹æã¯ãã»ãŒç¢ºç«ããäºå®ããšæŽçãããŠãããåœç«ããç ç©¶ã»ã³ã¿ãŒã®ãããªã¹ã¯è©äŸ¡ã§ãããããªé€èã«ããèãããªã¹ã¯äœäžã®ç§åŠçæ ¹æ ã¯ã確å®ããšå€å®ãããŠããŸãã
ãã®ç¹ã匷ãè£ä»ããã®ããUemura ãã New England Journal of Medicine ã«çºè¡šããæ¥æ¬äººã察象ã«ãã远跡ç ç©¶ã§ãããããªèææè 1,246 人ãå¹³å 7.8 幎远跡ãããšãã 36 人ïŒ2.9%ïŒãèãããçºçããäžæ¹ãéææè 280 人ãã㯠1 äŸãèãããçºçããŸããã§ããïŒUemura N, et al. N Engl J Med 2001;345:784-9ïŒãããããªã«ææããŠããªã人ããã¯ãŸãèããã¯åºãªãããšããäºå®ãã20 幎以äžåãã確èªãããŠããŸãã
åœéæ¯èŒã§ãåãæ§é ãèŠããŸããç±³åœåœç«ããç ç©¶æïŒNCIïŒã® SEER ããŒã¿ã§ã¯ãç±³åœã«ãããèããã¯å šæ°èŠãã蚺æã® çŽ 1.5% ã«ãšã©ãŸãåžå°å¯ãã®ãããNHANES ç±æ¥ããŒã¿ã§ã¯ç±³åœã®ãããªèææç㯠30ã36%ãäžæ¹ã®æ¥æ¬ã¯ãããªèææçãçŽåæ°ã§ãIARC ã® GLOBOCAN ã§ã¯æ±ã¢ãžã¢ïŒæ¥æ¬ã»äžåœã»éåœïŒã®èããå¹Žéœ¢æšæºå眹æ£çã¯æ¬§ç±³ã® çŽ 4ã6 å ãšæšèšãããŠããŸãããããªèææçã®å·®ãããã®ãŸãŸèãã眹æ£çã®å·®ãšããŠè¡šããŠããããšèŠãŠå€§ããã¯å€ããŸããã
ãããŸã§ã®æ§é ãæŽçãããšãåå®®é žãããšèããã®èšèšã¯ ã»ãŒå¯Ÿç§°ã§ãã

ããã§ç»å Žããã®ã ABC æ€æ»ã§ããæ¡è¡ã ãã§ãããªèæäœãšèç²èã®è瞮床ïŒããã·ãã²ã³å€ïŒã枬ããA 矀ïŒãªã¹ã¯äœïŒãã D 矀ïŒãªã¹ã¯é«ïŒã«ãªã¹ã¯ãå±€å¥åããæ€æ»ã§ã被ã°ãã誀å¥ãªã¹ã¯ããããŸããã
ãã ããããã¯å€§äºãªå眮ãã§ãããABC æ€æ»ã¯ããããçŽæ¥èŠã€ããæ€æ»ãã§ã¯ãããŸããããããŸã§ããèããã«ãªããããäœè³ªãããåããæ€æ»ã§ãããªãŠã ãèã«ã¡ã©ã® å®å šãªä»£æ¿ãšããŠåçŽæ¯èŒãã話ã§ã¯ãªãããšãããšããã¯æŒãããŠãããŸãã
ããã§ãããå šå¡ã«äžåŸã§ããªãŠã ãã§ã¯ãªããæ¡è¡ã® ABC ã§ãªã¹ã¯ãåããé«ãªã¹ã¯è ã ãæ©æçãæŸããèã«ã¡ã©ã«ã€ãªããäºæ®µèšèšã®æ¹ããæ€æ»ãšããŠã¯ãã£ãšãŸã£ãšãã«èŠãããæ©æçãæŸããå èŠé¡è³æºããå¿ èŠãªäººã«å¹ççã«å±ããããšããèšèšã§ãã
å®è£ ã®åäŸããããŸããæšªé è³åžã¯ 2012 幎床ïŒå¹³æ 24 幎床ïŒããåžã®èããæ€èšºã§èéš X ç·ïŒããªãŠã ïŒãå®å šã«å»æ¢ã㊠ABC æ€èšºã«åãæ¿ãã2019 幎床ããäžåŠ 2 幎çã察象ã«ãããããªå¯Ÿçäºæ¥ïŒäžæ¬¡æ€æ»ããé€èåŸã®ç¢ºå®æ€æ»ãŸã§å šé¡å ¬è²»è² æ ïŒã2023 幎床ã«ã¯ 20 æ³ã»30 æ³ã«ãç¡æå蚺åžãçºéãã圢ã§è¥å¹Žå±€ã«æ¡å ããŠããŸããäœè³çã 2016 幎床ããäžåŠ 3 幎çå šå¡ã察象ã«ããè¥å¹Žè ãããªæ€èšºãå§ããŠãããIARC 㯠2025 幎ã«äººå£ããŒã¹ã®ãããªã»ã¹ã¯ãªãŒãã³ã° & é€èæŠç¥ã®å®è£ ã¬ã€ãã³ã¹ãå ¬éããŠããŸãã
ãèãããæ©æçºèŠãããã ãã§ãªããèããã«ãªãæåã§ä»å ¥ããããšããæ¹åã®åãããèªæ²»äœã¬ãã«ã§ãæµ·å€ã§ãå§ãŸã£ãŠããããšããããšã§ãã
â€ããã§ãå€ãããªãçç±ïŒããªãŠã åŽ + ABC åŽãäž¡æ¹ã®å£ïŒ: ããã§ãããªãŠã ã¯æ®ããABC ãžã®åãæ¿ãã¯ãªããªãåºãããŸãããçç±ã¯äºéã«çµ¡ãã§ããŸãã
ããªãŠã åŽ: å¥èšºæ©é¢ã®æ€æ»ã©ã€ã³ãèªåœ±äœå¶ãæ¢åèšåãæ€æ»ããžãã¹ãå¶åºŠæ £æ§ããããŸããååŽçã®èªæ²»äœèª¿æ»ã§ããèå èŠé¡æ€èšºã宿œããªãçç±ãšããŠãæœèšã»èšåããªãã71.7%ãã粟床管çäœå¶ãæŽããªãã35.9%ããå§èšã§ããäºæ¥è ããªãã48.6% ãæãã£ãŠããŸããèšåã»äººæã®äžè¶³ãçæã§è§£æ¶ããªãæ¹ããæ¢åã®ããªãŠã æ€æ»äœå¶ãæž©åããããããšããèŠæ¹ãã§ããŸãã
ABC åŽïŒçä¿èŸŒã¿ïŒ: åœç«ããç ç©¶ã»ã³ã¿ãŒã®èããæ€èšºã¬ã€ãã©ã€ã³ã§ã¯ããããªèæäœãããã·ãã²ã³æ³ïŒ= ABC æ€æ»ïŒã¯ ã察çåæ€èšºãšããŠã¯æšå¥šãããŸããã ãšãããŠããŸããçç±ã¯ãæ»äº¡çæžå°å¹æãå€å®ãã蚌æ ãååã§ãªãããšãããã®ã§ããããã¯åè«ãããããè«ç¹ãªã®ã§æèšããŠãããŸãã
ãã ããã®ãæ»äº¡çæžå°å¹æã®ãšããã³ã¹ããšããåºæºãã®ãã®ããé·å¹Žå®æœãããŠããå€ãæ€æ»ã«æå©ã«åããŸããããªãŠã ã¯äœå幎ã宿œãããŠãããããæ»äº¡çæžå°å¹æã®ããŒã¿ãç©ã¿äžãã£ãŠãããABC ã®ãããªæ°ããèšèšã¯ããŸãããŒã¿èç©ã«æéããããããã蚌æ äžååãã«ãªãããããæé軞ã®é察称æ§ããçµæãšããŠå€ãæ€æ»ãæž©åããæ§é ã«ãªã£ãŠããããšããããšã§ãã
ã¬ã€ãã©ã€ã³èªäœããæ¢åã®æ€æ»äœå¶ãç¶æããã€ã³ã»ã³ãã£ãã®äžã§äœãããŠãã â ããèŠããšãããªãŠã ãæ®ãçç±ããABC ãæšå¥šãããªãçç±ããåãæ§é ã«èŠããŠããŸãã
â¢HPV æ€æ»ã»èªå·±æ¡å â 现èã®èŠãç®ãèŠãæ€æ»ãšãåå ãŠã€ã«ã¹ã調ã¹ãæ€æ»ã®å·®
â äœã®ããã®æ€æ»ã: åå®®é žããã®æ©æçºèŠã»åããç å€ã®çºèŠãç®çã§ããçŸåšã®æ¥æ¬ã®äž»è»žã¯ 现è蚺ã§ãå»åž«ãåå®®é žéšãã现èãæ¡åããé¡åŸ®é¡ã§èŠãç®ãå€å®ããæ€æ»ã§ãã
â¡æ€æ»ã®åŒ±ç¹: 匱ç¹ã¯äºã€ãããŸããã²ãšã€ã¯ç²ŸåºŠé¢ã现è蚺ã¯ã现èã®èŠãç®ããé¡åŸ®é¡ã§å€å®ããæ€æ»ã§ãåå ãŠã€ã«ã¹ãã®ãã®ã調ã¹ãŠããããã§ã¯ãããŸãããããã²ãšã€ã¯å蚺è è² æ ãå»åž«æ¡åã®çã¿ã»æ¥ããããã»å»çæ©é¢ã«è¡ãå¿ççããŒãã«ããå蚺çãæŒãäžããŠããŸãã
â¢æ°å: åå®®é žããã¯ãã»ãŒ 100% ã HPV ã®ææãèæ¯ã«çºçããŸããWalboomers ãã 1999 幎ã«çºè¡šããäžç 22 ã«åœã»çŽ 1,000 æ€äœèŠæš¡ã®è§£æã§ã¯ãåå®®é žããçµç¹ã® 99.7% ãã HPV ãæ€åºããããšå ±åãããŠããŸãïŒWalboomers JM et al. J Pathol 1999;189:12-19ïŒãåœç«ããç ç©¶ã»ã³ã¿ãŒããåå®®é žããã® 95% 以äžã¯ HPV ã®æç¶ææãåå ããšæç€ºããŠããŸãã
ãããŠæ€åºæåºŠã§ããã«ããã§è¡ãããç¡äœçºåæ¯èŒè©Šéšã§ã¯ã1 åã®æ€æ»ã§ã® CIN2+ïŒäžç床ç°åœ¢æä»¥äžãåå®®é žããã®äžæ©æåïŒæ€åºæåºŠãã现è蚺åç¬ã§ 55.4%ãHPV æ€æ»åç¬ã§ 94.6% ãšå ±åãããŠããŸãïŒMayrand MH et al. N Engl J Med 2007;357:1579-88ïŒã1 åãããã ãšã现è蚺ã¯ååè¿ããåãããŒãããããšããããšã§ããæ¥æ¬ã®æ€èšºã¬ã€ãã§ã现è蚺ã®åããç 倿€åºç²ŸåºŠã¯ãããã 7 å²ããšãããã®ã¯ãè€æ°åã®ç¶ç¶å蚺ãåæã«ããæšèšå€ã§ãååã§ã¯ãã®å·®ãã¯ã£ããåºãŸãã
ã€ãŸããã现èã®èŠãç®ãèŠãæ€æ»ããããåå ãŠã€ã«ã¹ã調ã¹ãæ€æ»ãã®æ¹ããåãããŒããå§åçã«å°ãªãããšããããšã§ãã
ãããŠèªå·±æ¡åã®ç²ŸåºŠã§ããArbyn ãã®æŽæ°ã¡ã¿è§£æïŒArbyn M et al. BMJ 2018;363:k4823, PMID: 30518635ïŒã§ã¯ãPCR ããŒã¹ã® HPV æ€æ»ã§ã¯ èªå·±æ¡åãšå»åž«æ¡åã®æåºŠã¯ã»ãŒåçïŒæåºŠæ¯ 0.99ã95% CI 0.97-1.02ïŒ ãšå ±åãããŠããŸãã
â£çŸä»£çãªä»£æ¿æ¡: WHO 㯠2021 幎ã«ãåå®®é žããæ€èšºã§ HPV DNA æ€æ»ãäžæ¬¡æ€æ»ãšããŠæšå¥šããèªå·±æ¡åãµã³ãã«ãå©çšå¯èœãšç€ºããŸããã
èªå·±æ¡åã§ HPV â éœæ§è ã ã现è蚺ãç²Ÿå¯æ€æ»ã«ã€ãªãäºæ®µèšèšã«åãæ¿ããã°ã粟床ã¯äžãããå蚺è ã®çã¿ãæ¥ãããããäžãããå蚺çãäžããã°ãçµæãšããŠæ©æçºèŠãå¢ããããšããæ§é ã§ããæµ·å€ã§ãå®è£ ãé²ãã§ããããªã©ã³ãã¯åœã¬ãã«ã§çްè蚺ãã HPV æ€æ»ãžç§»è¡ããããã§èªå·±æ¡åããªããã€ã³æäŸããã³ããŒã¯ã¯ 2017 幎ããéŠéœåã§éå蚺è åãã«èªå·±æ¡åãããããªããã€ã³æäŸããªãŒã¹ãã©ãªã¢ã¯ 2022 幎 7 æããå šå¥³æ§ãèªå·±æ¡åãéžæã§ããåœ¢ã«æ¡å€§ããŠããŸãã
â€ããã§ãå€ãããªãçç±: ããã§ãæ¥æ¬ã§ã¯ãäºæ®µéã®é ãããããŸãã
å»åž«ãå»çæ©é¢ã§æ¡åãã HPV æ€æ»åç¬æ³ïŒå»åž«æ¡åçã® HPV äžæ¬¡æ€æ»ïŒã¯ã2024 幎 4 æãããèŠä»¶ãæºããèªæ²»äœã¯äœæ°æ€èšºã«è¿œå ã§ããå¶åºŠã«ãªããŸããããšããããå®éã«å°å ¥ããã®ã¯å¿æšåžã»åå åžã»æšªæµåžã»è²é¡åžã® 4 èªæ²»äœã«ãšã©ãŸããŸãïŒ2025 幎æç¹ïŒãèªå·±æ¡åã«è³ã£ãŠã¯ãå¶åºŠå°å ¥ã®è°è«ããã»ãšãã©åºãã£ãŠããŸããã
ããã«ã¯ã现è蚺äžå¿ã»å»åž«æ¡åäžå¿ã§çµãŸããŠããæ€èšºäœå¶ãç£å©Šäººç§é åã®å°éè·å£äœéã®ç«å Žã®éããå»çæ©é¢ã®å蚺æ©äŒãç¶æãããåãçŸå Žãªãã¬ãŒã·ã§ã³ãžã®ãã ããã絡ãã§ããŸããå蚺è ããèŠãã°ããã£ãšæ¥œã§ããã£ãšåããããã粟床ãé«ãéžæè¢ãããã®ã«ãå¶åºŠã¯ãªããªãå€ãããªãããšããããšã§ãã
å ±éããæ§é â å蚺è ç®ç·ããæäŸåŽã®éœåãåªå ããããã
èºã¬ã³ãã²ã³ãããªãŠã + ABCã»ãããªãHPV èªå·±æ¡åã3 ã€ã®å ·äœäŸã«å ±éããŠããã®ã¯ãæè¡ãåœéæšæºã§ã¯ãè§£ãããã®ã«ãæ¥æ¬ã§ã¯åããªãããšããçŸè±¡ã§ãã
ãããŠãåããªãçç±ã芳å¯ããŠãããšã䌌ããããªãã¿ãŒã³ãèŠããŠããŸãã
æ¢åã®æ€èšºäœå¶ãç¶æãããå
æ¢åææãžã®ãã ãã
å»åž«æ¡åãåæãšããæ€èšºäœå¶ãžã®åºå·ïŒç¹ã« HPVïŒ
å蚺è ç®ç·ãããæäŸåŽã®éœåãåªå ãããŠããããã«èŠããæ§é
ãå蚺è ã«ãšã£ãŠäœã楜ã§åççããããããèª°ãæ€æ»ãæ ããããéãæ±ããã
å»çå°éè·ã®ãã©ã€ããè·èœå£äœã®çžåŒµãæèããåççãªå¶åºŠå€æŽãé ãããããšã¯ãããŸãã
ãã¡ããã粟床管çãå®å šæ§ã軜èŠããŠããããã§ã¯ãããŸããã
ãã ãå蚺è ã«ãšã£ãŠããæ¥œã§ãããåãããããåœéçã«ãåçæ§ãããéžæè¢ãèŠããŠããã®ã«ãããããªããªãåºãããªãã®ã§ããã°ããå°éå®¶ãæ éã«èŠãŠãããããã§çã¥ããã®ã¯èŠããã
ããã«ã¯ãæ¢åã®æ€èšºäœå¶ãç¶æãããåããããšèŠãæ¹ãèªç¶ã§ãã
äžå»åãšæ€èšºåŽåè·¯ â ä¿éºèšºçãšå¯Ÿçåæ€èšºã®2ã€ã®ããã«ããã¯

ãããŸã§ã®æ§é ãå¶åºŠã¬ãã«ã§åçç£ãããä»çµã¿ããæŒãããŠãããŸããæ¥æ¬ã®å»çå¶åºŠã«ã¯ã倿Žãæ¢ãããããã«ããã¯ãå°ãªããšã 2 系統ãããŸãã
ã²ãšã€ç®ã¯ãäžå€®ç€ŸäŒä¿éºå»çåè°äŒïŒäžå»åïŒ ãšãã蚺çå ±é ¬ãæ±ºããæ©é¢ã§ãã
äžå»åã¯æ¯æåŽå§å¡ïŒå¥åº·ä¿éºçµåãçµæžå£äœïŒã蚺çåŽå§å¡ïŒå»åž«äŒã»æ¯ç§å»åž«äŒã»è¬å€åž«äŒãªã©ïŒãå ¬ç代衚ã®äžè æ§æã§éå¶ãããŠããŸãã蚺çå ±é ¬æ¹å®ã¯ 2 幎㫠1 åè¡ããã忀æ»ã»èšºçè¡çºã®ä¿éºç¹æ°ã決ãŸããŸãã
蚺çåŽå§å¡ã®äžæ žã¯æ¥æ¬å»åž«äŒãå ããŠããã蚺çæïŒç¹ã«éæ¥å»ïŒã®æåãåæ ãããããæ§é ã§ããçµæãšããŠã鿥å»ã«æå©ãªç¹æ°èšèšããæ¢åã®æ€æ»ã»èšºçæ çµã¿ãç¶æããæ¹åã®æ¹å®ãèµ·ãããããšææãããŠããŸãã
ããšãã°ãçæŽ»ç¿æ £ç 管çæãç¹å®å¥èšºã®ã¡ãã¥ãŒãåšå® å»çã»ãªã³ã©ã€ã³èšºçã®ç¹æ°èšèšãªã©ãå»åž«äŒã®äž»åŒµãéã£ã圢跡ãéæã«ãããŸãã
ããã¯ãå»åž«äŒãæªãããšããåäººæ»æã®è©±ã§ã¯ãªããå¶åºŠèšèšã®ã€ã³ã»ã³ãã£ããšããŠãæ¢åã¹ããŒã¯ãã«ããŒã®å©å®³ã匷ãåæ ãããæ§é ã«ãªã£ãŠããããšããäºå®ã§ãã
AI ã§ããã£ãšå¹ççã«ã§ããã¯ãããäºé²ã®æ¹ãå®ãæžãã¯ãããšããã¢ã€ãã¢ãæµ®ããã§ãããã®ææ¡ãå¶åºŠãšããŠéãã«ã¯ããã®äžå»åãšããããã«ããã¯ãéãå¿ èŠããããŸãã
ãµãã€ç®ã®ããã«ããã¯ã¯ã察çåããæ€èšºãæ±ºããæ€èšºåŽåè·¯ã§ãã
èªæ²»äœã®å¯Ÿçåããæ€èšºã§äœãæ€æ»é ç®ã«å ¥ãããïŒããªãŠã ãæ®ãããABC ãå ¥ããããHPV æ€æ»åç¬æ³ãå°å ¥ãããïŒã®æææ±ºå®ã¯ãäžå»åãšã¯å¥ç³»çµ±ã§é²ã¿ãŸããåœç«ããç ç©¶ã»ã³ã¿ãŒã®ã¬ã€ãã©ã€ã³ â ååŽçãããæ€èšºã®ããæ¹ã«é¢ããæ€èšäŒãâ ã¢ãã«äºæ¥ â æéæ¹æ£ããšããåè·¯ã§ãã
ãã®æ€èšºåŽåè·¯ã«ããé¢é£ããåŠäŒãæ€æ»æ©åšã¡ãŒã«ãŒãé·å¹Žã®æ€æ»äœå¶ã«æè³ããŠããå¥èšºæ©é¢ã®å©å®³ãåæ ãããããæ§é ããããŸãããæ»äº¡çæžå°å¹æã®ãšããã³ã¹ãååãããšãããäžèŠç§åŠçã«èŠããåºæºããé·å¹Žå®æœãããŠããæ€æ»ã«æå©ã«åããããå€ãæ€æ»ã»ã©æšå¥šã«æ®ããããã
ã€ãŸããä¿éºèšºçã®å€ä»ããæ±ºããäžå»åãšã察çåæ€èšºã®æ€æ»é ç®ã決ããæ€èšºåŽåè·¯ãšã婿š©ããã«ããã¯ãå°ãªããšã 2 系統ãããŸããAI ã§ããã£ãšè¯ãæ€æ»ãã§ããããäºé²åã«çµã¿æ¿ããããããšããã¢ã€ãã¢ãæµ®ããã§ãããã® 2 系統ã®ã©ã¡ããããããã¯äž¡æ¹ãéãå¿ èŠããããŸãã
æµ·å€å¶åºŠãšã®æ¯èŒ â ãå æ¬æããåãã§ã¯ãªã
誀解ãé¿ããããã«ãæµ·å€å¶åºŠãšã®æ¯èŒãæŽçããŠãããŸãã
äžéšã®åœã§ã¯ãå»çæäŸåŽãäºé²ãéçå鲿¢ã«åãããããä»çµã¿ããããŸãã
è±åœïŒNHSïŒ: GPïŒå®¶åºå»ïŒã¯äººé æãïŒç»é²æ£è æ°ã«å¿ããŠå ±é ¬ïŒãã²ãŒãããŒããŒå¶åºŠïŒå°éå»ã«ãããã«ã¯ GP ã®ç޹ä»ãå¿ é ïŒ
ç±³åœïŒHMOïŒ: å æ¬çãªå»çãã©ã³ã§ãæäŸåŽãäºé²ã«åããã€ã³ã»ã³ãã£ããçµã¿èŸŒãŸããŠãã
ãã€ã: 瀟äŒä¿éºããŒã¹ãå®¶åºå»å¶åºŠã®éžæå¶
ãã©ã³ã¹: 䞻治å»å¶åºŠãšå°éå»ã®ããã¯ã¹
ãããã®åœã§ã¯ããæ£è ãéçåããªãã»ã©ãå»çæäŸåŽã«ãã¡ãªãããåºãããããšããä»çµã¿ããäžéšã®é åã«çµã¿èŸŒãŸããŠããŸãã
ãã ããããã¯ãå æ¬æããåã§åºæ¥é«æããæªããšããåçŽãªè©±ã§ã¯ãããŸãããæµ·å€å¶åºŠã«ã課é¡ããããŸãã
è±åœ NHS ã¯è¿å¹Žãé«éœ¢åãšè²¡æ¿éŒè¿«ã§åŸ æ©æéã®é·æåãæ·±å»åããŠããŸããå°éå»ã®äºçŽãŸã§æ°ã¶æåŸ ã¡ããšãããã¥ãŒã¹ãããèããŸããç±³åœ HMO ã¯ãå¿ èŠãªå»çãŸã§æå¶ãããŠãããããããã¯ãŒã¯å€ã®å»çæ©é¢ã«ããããªãããšããæ¹å€ããããŸãããã€ãããã©ã³ã¹ããããããå¥ã®èª²é¡ãæ±ããŠããŸãã
æŒãããŠããããã®ã¯ããå¶åºŠãéãã°ãå»çæ©é¢ã®åççãªè¡åãå€ããããšããç¹ã§ãã
æ¥æ¬ã®åºæ¥é«æãäžå¿ã®å¶åºŠã§ã¯ã蚺çè¡çºãå¢ãããããšãåçå¢ã«çŽçµããŸããå æ¬æããäººé æãã®å¶åºŠã§ã¯ãéçåãé²ãããå¹çããæ²»ããããšãåç確ä¿ã«ã€ãªãããŸãã
AI ãäºé²ã»ç¶ç¶æ¯æŽã®é åã§å¹ãããã«ãªã£ãæä»£ãåŸè ã®å¶åºŠèšèšã®æ¹ããAI ã®äŸ¡å€ãåŒãåºããããããšããã®ã¯æ§é çã«èšãããã§ãã
å»ç AI ããåãå£ã«ã¶ã€ãã
ãããŸã§èŠãŠãããåççã§ãå€ãããªãå»çãã®æ§é ã¯ãå»ç AI ãåºãŠããŠãåºæ¬çã«åãã§ãã
AI ã§èšºæç²ŸåºŠãäžãããAI ã§äºé²åã®ä»å ¥ãçµã¿ããããªããAI ã§å»çè³æºãå¹ççã«é åã§ããã
ããã§ãããã®ææ¡ãå¶åºŠãšããŠéãã«ã¯ããããŸã§èŠãŠããäžå»åãšæ€èšºåŽåè·¯ãšãã 2 系統ã®ããã«ããã¯ãéãå¿ èŠããããŸãããããŠããã®ã©ã¡ãã«ããæ¢åã¹ããŒã¯ãã«ããŒã®å©å®³ãåæ ãããããæ§é ããããŸãã
å»ç AI ãåºãã£ãŠããçµå±ã®ãšããåãããŠããã®ã¯ããã®äžã«ããå¶åºŠãšå©æš©ã®åŽã§ãã
ãã ããåžæããããŸããå»ççã®äžã ãã§è°è«ãéããŠããç¶æ ããæè¿å°ããã€æºããå§ããŠããããã§ãã
ã²ãšã€ã¯ãå¥ä¿çµåäž»å°ã®äºé²ã€ã³ã»ã³ãã£ãã®åãã§ããå¥åº·ä¿éºçµåã¯å å ¥è ã®å»çè²»ãæãããã®ã§ãäºé²ãšéçå鲿¢ã«çµæžçåçæ§ããããŸãã2025 幎床ã«ãäºé²ã»å¥åº·ã¥ããæšé²åªè¯çµååçåŽå倧è£èªå®ã»è¡šåœ°å¶åºŠããå§ãŸããå¥ä¿çµåãäºé²ã«æè³ããåããå¶åºŠãšããŠåŸæŒãããå§ããŸããã
ããã²ãšã€ã¯ããã©ãããã©ãŒããŒåŽããã®åãã§ããAI å蚺㮠Ubieããªã³ã©ã€ã³å»çã® MICINããã«ã¹ã±ã¢ã¢ããªå瀟ããå»çæ¥çã®å€åŽãããäºé²ã»æ©æä»å ¥ãã®ãµãŒãã¹ãåºããŠããŸãããããã¯ä¿éºèšºçã®æ å€ã§ã䟡å€ãçãŸããèšèšã«ãªã£ãŠããã婿𩿧é ã®å€åŽããåžå Žãäœãã€ã€ãããŸãã
å ããŠãååŽçãåããŠã¯ããŸãããå»ç DX 什åããžã§ã³ 2030ãã§ã¯äºé²ãšéçåäºé²ãéç¹åããã2024 幎床ã®èšºçå ±é ¬æ¹å®ã§å»ç DX æšé²äœå¶æŽåå ç®ãæ°èšãããŸããã2025 幎 9 æ 1 æ¥ã«ã¯ AI æšé²æ³ãå šé¢æœè¡ãããŠããŸãã
ãã ãããããã®åããæ¢åã®å©æš©æ§é ãã©ããŸã§åããããã¯ããŸã èŠããŠããŸãããäžå»åãšããããã«ããã¯ãæ€èšºåŽåè·¯ãšããããäžã€ã®ããã«ããã¯ããããŠã¬ã€ãã©ã€ã³ãã®ãã®ãå€ãæ€æ»ã«æå©ã«äœãããŠããæ§é ãæ®ã£ãŠããéãã蚺çå ±é ¬æ¬äœãæ€èšºã¡ãã¥ãŒã®èšèšã倧ããå€ããã®ã¯é£ããããšããèŠç«ãŠããããŸãã
å»ççã®å€åŽãããæ£è ãçµæžåçæ§ãæã€ã¹ããŒã¯ãã«ããŒã声ãäžãç¶ããããšãããã¶ãå¿ èŠã§ãã
ãŸãšã â æè¡ã¯æ¥ãŠãããåããªãã®ã¯å¶åºŠãšå©æš©ã§ãã
å»ç AI ã®æ¬åœã®é害ã¯ãæè¡ãæªçãªããšã ãã§ã¯ãããŸããã
AI 以åãããæ¥æ¬ã®å»çã«ã¯ãåççã«å€ããæ¹ããããããªã®ã«å€ãããªããã®ãããããŸãã
èºã¬ã³ãã²ã³ã
ããªãŠã + ABCã»ãããªå¯Ÿçã
HPV èªå·±æ¡åã
å蚺è ããèŠãã°ããã£ãšæ¥œã§ããã£ãšåççã§ããã£ãšäºé²ã«å¯ããéžæè¢ãããã
ããã§ãå¶åºŠã¯å€ããã«ããã
çç±ã¯ãæè¡ã§ã¯ãããŸããã
æ¢åã®æ€æ»äœå¶ãå¥èšºæ©é¢ã®åçæ§é ãå°éè·å£äœã®ç«å Žãå»åž«äŒã»åŠäŒã®åœ±é¿åã蚺çå ±é ¬ãæ€èšºæéãã¬ã€ãã©ã€ã³ã®ä¿å®æ§ã
ãããããã®ãè€éã«çµ¡ãã§ããããã§ãã
ã¯ã£ããèšãã°ãããã¯å©æš©ã§ãã
ãã¡ããããã¹ãŠã®å»åž«ãå»çæ©é¢ãæªããšãã話ã§ã¯ãããŸãããçŸå Žã§å蚺è ãšåãåã£ãŠçæ¯ã«èšºçããŠããå»åž«ã¯å€§å¢ããŸãã
ãã ãå¶åºŠãšããŠãå€ããªãæ¹ãéœåã®ãã人ãã¡ããå€ãããããã®çµæãå蚺è ã«ãšã£ãŠåççãªéžæè¢ãåºããã«ããã
ãã®æ§é ãèŠãªããŸãŸãå»ç AI ã®æªæ¥ãèªã£ãŠãããã¶ãæ¬è³ªãå€ããŸãã
AI ã§èšºæã§ããã
AI ã§äºé²ã§ããã
AI ã§å»çè³æºãå¹çåã§ããã
ããã§ããå¶åºŠãåããªããã°ç€ŸäŒã¯å€ãããŸããã
å»ç AI ã®æ¬äžžã¯ãæè¡ã§ã¯ãªãããã®æè¡ãéãå¶åºŠãšå©æš©ã®æ¹ã«ããã
å¶æ¥ã»ããŒã±ãã£ã³ã°ã»äŒç»ãªã©ãå»çæ©é¢ã®å€åŽã§ AI ååã远ããããæ¹ãèŠãã¹ãã¯ãæè¡è«ã®æ¹ã§ã¯ãªãããã¡ãã®å¶åºŠãšå©æš©ã®æ¹ãããããŸãããæè¡ã¯ããæ¥ãŠãããåãããŠããã®ã¯ããã®äžã«ããæ§é ã®æ¹ã§ãã
ãAI ã§è§£ãããã®ãšãAI ã§ç€ŸäŒãåããã®ããã ã«ã¯ãããªãæ·±ãæºããããŸãã
ããããŠèªã¿ãã
AI ã§å®è¡ã³ã¹ãã¯äžããã倿ã³ã¹ãã¯äžãããªãããšããé察称æ§ãæžããŸãããæ¬èšäºã®å¶åºŠè«ããæè¡ãã§ããŠããå€æãšæææ±ºå®ãã®åŽã§è©°ãŸãããšããååã®æ§é ã§ãã
AI æä»£ã«è©äŸ¡ããã人ã®å ±éç¹ãšããŠãéåæã»ã³ãµãŒããæžããŸãããå»ç AI ã®è°è«ã§ãæè¡è«ã ãã§ã¯äœãããããããšæããæèŠãããã¶ããã®èšäºã®åºçºç¹ã«ãªã£ãŠããŸãã
XãSubstackã§ãçºä¿¡äž
Xã§ã¯AIãŸããã®ææ°ååãæ¥ã ã®æ°ã¥ãããSubstackã§ã¯å°ãæ·±æãããèããæžããŠããŸãã